BI 1821736 / Boehringer Ingelheim - LARVOL DELTA

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer (clinicaltrials.gov) - P1 | N=10 | Terminated | Sponsor: Boehringer Ingelheim | Trial completion date: Jan 2027 ➔ Apr 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jan 2026 ➔ Apr 2025; Sponsor decision

Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Suspended ➔ Active, not recruiting | N=27 ➔ 10

Enrollment change • Enrollment closed • Oncology • Solid Tumor

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer (clinicaltrials.gov) - P1 | N=27 | Suspended | Sponsor: Boehringer Ingelheim | Trial completion date: Nov 2025 ➔ Jan 2027 | Recruiting ➔ Suspended | Trial primary completion date: Nov 2024 ➔ Jan 2026

Metastases • Trial completion date • Trial primary completion date • Trial suspension • Oncology • Solid Tumor

Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors. (ASCO 2024) - P1 | "BI 1821736 is a genetically engineered pseudotype variant of VSV-GP encoding an immune-stimulatory cargo. A total of six patients have received BI 1821736 as of January 29, 2024. Patients are currently being enrolled to dose level 2."

Clinical • IO biomarker • Metastases • Oncolytic virus • CNS Disorders • Infectious Disease • Oncology • Solid Tumor

Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors (ESMO-IO 2023) - No abstract available

Clinical • Metastases • Oncolytic virus • Oncology • Solid Tumor

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Jan 2027 ➔ Nov 2025 | Trial primary completion date: Jan 2026 ➔ Nov 2024

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2025 ➔ Jan 2027 | Trial primary completion date: Nov 2024 ➔ Jan 2026

Enrollment open • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial • Oncology • Solid Tumor